The share price of Cerevel Therapeutics Holdings Inc. (CERE) rose 52.35% to trade at $19.15 at last check in premarket trading today. Cerevel stock closed on Monday at $12.57, down 3.01% from its previous close of $12.96. Volume of CERE stock traded was 0.35 million shares, which was higher than the average volume over the last three months, 302.67K shares. During the trading session, the CERE stock oscillated between $12.50 and $13.25.
CERE had an earnings-per-share ratio of -2.41. Over the past five sessions, CERE has lost -8.78% of its value. On a month-to-month basis, CERE has lost -24.19% of its value. With a 50-day moving average of $13.85 CERE stock is above its 200-day moving average of $13.59. A RSI of 39.76 is currently being displayed on the CERE stock. After the topline results of a clinical trial, CERE stock has surged.
The trial was held for what purpose?
Cerevel’s goal is to uncover the mysteries of the brain with the goal of treating neurological diseases. A targeted neuroscience approach is used by CERE in its efforts to treat diseases combining expertise in neurocircuitry and receptor selectivity. CERE’s pipeline consists of five clinical-stage investigational therapies and several pre-clinical compounds that may be used to treat a variety of neurological diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorders. CERE has its headquarters in Cambridge, Mass., and is actively researching new technology modalities through internal initiatives, external collaborations, or possible acquisitions.
Cerevel today announced positive results from its Phase 1b clinical trial involving CVL-231, a muscarinic M4-selective positive allosteric modulator (PAM).
- A 6 week period of continuous dosing of CVL-231 and a placebo showed similar discontinuation rates: 22% each. In summary, CERE’s CVL-231 was well tolerated by trial participants.
- In addition, both the daily dose of 30 mg and the twice-daily dose of 20 mg demonstrated antipsychotic activity with overall well-tolerated profiles when compared to placebo.
- The positive and negative syndrome scale (PANSS) total score decreased from baseline by 19.5 points and points for the placebo group decreased by 12.7 points, both statistically significant and clinically meaningful reductions.
- The PANSS total score decreased by 17.9 points in the CERE group compared with the placebo group after taking 20 mg twice a day of CVL-231.
What CERE plans to do next?
In light of these encouraging results, Cerevel (CERE) is confident that a targeted muscarinic therapy that targets the M4 receptor can provide clinically meaningful benefits in schizophrenia treatment. CERE is going a long way towards unraveling how the muscarinic pathway can best be leveraged to better treat schizophrenia, in part by developing a drug that is several hundred times more selective for M4 receptors than M1, M2, M3, and M5.
